SWOG clinical trial number
CTSU/A021501

Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

Closed
Phase
Abbreviated Title
Preop Extended Chemo vs. Chemo + Plus Hypofractionated Radiation for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Status Notes
Effective Monday, May 06, 2019 at 4:30 PM ET, Alliance A021501 will be permanently closed to new patient pre-registration (Step 0) as it has met its accrual goal.

Activated
12/15/2016
Participants
ALLIANCE, ECOG-ACRIN, NRG, SWOG

Research committees

Gastrointestinal Cancer

Treatment

5-Fluorouracil Irinotecan Leucovorin Calcium Oxaliplatin

Publication Information Expand/Collapse

2024

Postoperative Complications Following Neoadjuvant Therapy and Surgery in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)

R Snyder;S Ahmad;D Segovia;T Zemla;Q Shi;E O'Reilly;J Herman;M Katz ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA); J Clin Oncol 42, 2024 (suppl 3; abstr 664), poster

Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)

R Snyder;T Zemla;Q Shi;D Segovia;S Ahmad;E O'Reilly;J Herman;M Katz Annals of Surgical Oncology Jul 15. doi: 10.1245/s10434-024-15670-6. Online ahead of print

PMid: PMID39008208

2022

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial

M Katz;Q Shi;J Meyers;J Herman;M Chuong;B Wolpin;S Ahmad;R Marsh;L Schwartz;S Behr;W Frankel;E Collisson;J Leenstra;T Williams;G Vaccaro;A Venook;J Meyerhardt;E O'Reilly JAMA Oncology Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319

PMid: PMID35834226 | PMC number: PMC9284408

2021

Alliance trial A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas

M Katz;Q Shi;J Meyers;J Herman;M Chuong;B Wolpin;S Ahmad;R Marsh;L Schwartz;S Behr;W Frankel;E Collisson;J Leenstra;A Venook;J Meyerhardt;E O'Reilly J Clin Oncol 39, 2021 (suppl 3; abstr 419); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), oral

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
100%
Open
Phase